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Abstract: Implantable drug delivery devices offer many advantages over other routes of drug 15 
delivery. Most significantly, delivery of lower doses of drug, thus, potentially reducing side-effects 16 
and improving patient compliance. 3D printing is a flexible technique, which has been subject to 17 
increasing interest in the past few years, especially in the area of medical devices. The present work 18 
focussed on the use of 3D printing as a tool to manufacture implantable drug delivery devices to 19 
deliver a range of model compounds (methylene blue, ibuprofen sodium and ibuprofen acid) in two 20 
in vitro models. Five implants designs were produced, the release rate varied, depending on the 21 
implant design and the drug properties. Additionally, a rate controlling membrane was produced, 22 
which further prolonged the release from the produced implants, signalling the potential use of 23 
these devices for chronic conditions. 24 
Keywords: implantable devices; sub-cutaneous; biodegradable; 3D printing; prolonged drug 25 
delivery 26 
 27 
1. Introduction 28 
Implantable drug delivery devices are those, which, when implanted into the body release drug 29 
at a defined rate and for a defined period. They offer advantages over other routes of drug delivery. 30 
They may achieve a therapeutic effect with lower drug concentrations [1–3] by potentially achieving 31 
higher drug concentrations at the site of interest, thus, reducing systemic drug exposure and 32 
minimising the potential for unwanted side-effects [4,5]. In addition, these devices allow personalised 33 
medicine, increased patient compliance [6] and prolonged delivery of treatment over weeks, months 34 
or years [7] in a device which may be removed if adverse effects require early termination of 35 
treatment [8,9]. Implantable delivery systems have been used for a range of clinical applications, most 36 
commonly contraception (e.g. Nexplanon® and Nuvaring®) and cancer treatment (e.g. Vantas®) [3,10]. 37 
Nexplanon® is a sub-cutaneous implant made from poly(ethylene vinyl acetate) which delivers 38 
etonogestral over a period of three years before requiring removal [11,12]. Vantas® is a sub-cutaneous 39 
implant made from a methacrylate based hydrogel which delivers the drug histrelin for the treatment 40 
of prostate cancer over a period of one year [13]. Implantable drug delivery devices also have the 41 
potential to be used for other conditions such as delivery of localised anaesthetics [14] or antibiotics 42 
[15]. 43 
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Currently, the majority of implantable drug delivery devices which are available, are 44 
manufactured from non-biodegradable polymers [10]. Thus, these implants require surgical removal 45 
once they have achieved their purpose. The surgical removal of non-biodegradable implants can 46 
often be more traumatic than their insertion [16]. Alternatively, biodegradable polymers offer the 47 
significant advantage of not requiring removal after their use, whilst still offering the potential for 48 
early removal, if required. They are designed to degrade naturally to products that can be excreted 49 
easily by the body [17]. Commonly used biodegradable and biocompatible polymers include: 50 
poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), and 51 
poly(caprolactone) (PCL). Previously, these polymers have been successfully used in nanoparticle 52 
based drug delivery systems and solid and microparticle parenteral implants [18] such as: Zoladex® 53 
(AstraZeneca), a solid PLGA parenteral implant for the delivery of goserelin for the treatment of 54 
prostate cancer in men, or breast cancer or endometriosis in women [19]; and Profact Depot® (Sanofi-55 
Aventis), which is also a solid PLGA parenteral implant, for the delivery of buserelin. Other 56 
parenteral implantable systems use polymeric microparticles as the delivery carrier including: 57 
Sandostatin LAR® (Novartis) to deliver octreotide; or Risperdal Consta® (Janssen) to deliver 58 
risperidone [20].  59 
The potential for personalisation of an implantable drug delivery device is substantial and 60 
becomes more likely due the increasing interest in 3D printing technologies. The high degree of 61 
flexibility and controllability of 3D printing would allow the preparation of tailored dosage forms 62 
with a release profile designed to exactly match the individual patient and condition to be 63 
treated [21]. Moreover, some of the disadvantages associated with 3D printing, such as high cost and 64 
speed, are improving as the technology becomes more widely used. The 3D printing approach to 65 
research newer (implantable) drug delivery devices can usher a new era of treatments to various 66 
diseases. 67 
The concept of drug delivery via an implantable device is not a new one. However, an 68 
implantable device that is: cheap; easily manufactured; biodegradable; biocompatible; and with a 69 
release rate that may be tailored to an individual patient, drug or clinical application is a very 70 
desirable goal, but one that is, as yet unachieved.  71 
Current research is often still focussed on the use of materials which are not biodegradable 72 
[22,23]. The aims of this study are: 1) to develop 3D printed implantable devices for drug delivery 73 
using biocompatible/biodegradable materials; and 2) to study the influence of the implant geometry 74 
on the drug release kinetics. For this purpose, we prepared different poly(lactic acid) and poly(vinyl 75 
alcohol) implant designs using fused deposition modelling (FDM) 3D printing technology. These 76 
implants were designed containing ‘windows’ of different sizes to allow drug release. Finally, a 77 
coating procedure using poly(caprolactone) was used to evaluate the possibility of obtaining more 78 
sustained release from these implants. The resulting implants were characterised using different 79 
techniques such as X-ray Micro Computer Tomography and texture analysis. The last step was to 80 
evaluate the drug release kinetics from these implants by using different model molecules and two 81 
in vitro models. 82 
2. Materials and methods  83 
2.1. Materials 84 
Granulate poly(lactic acid) (PLA) (Ingeo™ Biopolymer 4043D) was purchased from 85 
NatureWorks (Minnesota, USA). Filament poly(vinyl alcohol) (PVA) was purchased from Ultimaker 86 
(Ultimaker, Netherlands). Methylene blue, ibuprofen sodium, poly(ethylene glycol) (PEG)  (MW = 87 
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1,000 Da), agarose powder and phosphate buffered saline (PBS) tablets pH 7.4 were purchased from 88 
Sigma-Aldrich (Dorset, UK). Sodium azide was purchased from Fluorchem Ltd. (Hadfield, UK). 89 
Ibuprofen acid was purchased from Pharminnova (Waragem, Belgium). Poly(caprolactone) (PCL) 90 
6506 (MW= 50,000 Da and PCL 2054 (MW=550 Da) were provided by Perstorp (Perstorp, Sweden). 91 
2.2. Methods 92 
2.2.1. Implant designs 93 
Hot-melt extrusion was used to produce the PLA filament, which would be used for the implants 94 
manufacture in combination with the PVA filament. PLA pellets were added to a filament extruder 95 
(3Devo, Utretch, The Netherlands) at an extrusion speed of 5 rpm and a filament fan speed of 70%. 96 
Finally, the temperature was adjusted through a control panel positioned at the side of the extruder, 97 
and it was between 170 and 190 °C, due to the existence of four heaters [24]. 98 
Hollow implants were designed using a computer-aided design (CAD) software and printed 99 
using an Ultimaker3 3D printer (Ultimaker, Geldermalsen, Netherlands) using Cura® software. The 100 
Ultimaker3 system was equipped with two 0.4 mm extruder nozzles equipped with PLA and PVA, 101 
respectively. The print speed was 70 mm/s, the print temperature used was 205°C, the build plate 102 
temperature was 85°C and the layer height used was 0.2 mm. Five implant configurations were 103 
designed and produced (Figure 1): (A) 2.5 x 40.0 mm PVA implant (weight 0.15 ± 0.001g); (B) 2.5 x 104 
40.0 mm PLA implant with one (1.0 x 38.0 mm) PVA ‘window’ (weight 0.13 ± 0.007g); (C) 2.5 x 40.0 105 
mm PLA implant with eight (1.0 x 1.0 mm) PVA ‘windows’ (weight 0.13 ± 0.001g); (D) 2.5 x 40.0 mm 106 
PLA implant with two (1.0 x 1.0 mm) PVA ‘windows’; (weight 0.14 ± 0.005g)and (E) 2.5 x 40.0 mm 107 
PLA implant with one (1.0 x 1.0 mm) PVA ‘window’ (weight 0.14 ± 0.003g). The thickness of the PVA 108 
‘window’ was 0.4 mm in all cases. Finally, implants were filled with a model compound by directly 109 
packing powder inside. 110 
Figure 1: Schematic showing the implant designs: (A) 2.5 x 40.0 mm poly(vinyl alcohol) (PVA) implant; (B) 111 
2.5 x 40.0 mm poly(lactic acid) (PLA) implant with one (1.0 x 38.0 mm) PVA ‘window’; (C) 2.5 x 40.0 mm 112 
PLA implant with eight (1.0 x 1.0 mm) PVA ‘window’s; (D) 2.5 x 40.0 mm PLA implant with two (1.0 x 1.0 113 
mm) PVA ‘windows’; and (E) 2.5 x 40.0 mm PLA implant with one (1.0 x 1.0 mm) PVA ‘window’. 114 
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Finally, MB loaded implants (Figure 1(B) implant design) were coated with a formulation 116 
containing 50/50 PCL 6506/PCL 2054. This particular PCL composition was used because the coating 117 
of the implants with only PCL 6506 yielded implants were not capable of releasing their MB cargo 118 
(data not shown). For this purpose, 5 g of this mixture was dissolved in 10 mL of dichloromethane 119 
(Merck, Darmstadt, Germany). Implants were coated following a dip-coating procedure using the 120 
previously prepared solution. The thickness of the resulting coating was measured using a digital 121 
calliper after pealing it from the implant. The coating showed a thickness of 0.11 ± 0.01 mm. 122 
 123 
2.2.2. Implant characterisation 124 
Optical coherence tomography (OCT) using an EX1301 OCT microscope (Michelson 125 
Diagnostics, Kent, UK) enabled visualisation of the dissolving PVA ‘windows’ and the drug within 126 
the filled implant. The morphology of the implants was evaluated using electronic and optical 127 
microscopy. A Hitachi TM3030 benchtop scanning electron microscope (SEM) (Tokyo, Japan) and a 128 
Leica EZ4 D digital microscope (Leica, Wetzlar, Germany) were used.  129 
X-ray Micro Computer Tomography (μCT) scans were performed on 3D printed implants 130 
following the same methodology reported by Matthew et al. and Dominguez-Robles et al [25,26] . 131 
Briefly, the 3D reconstruction volumes and inner structures of the implants were observed by using 132 
a Bruker Skyscan 1275 system (Bruker, Germany) with a Hamamatsu L11871 source. The microfocus 133 
of the X-ray source of the micro-CT scanner had maximum voltage of 40 kV and maximum of 250 134 
μA. Samples were mounted vertically on dental wax and positioned 59.791 mm from the source, 135 
where camera to source distance was 286 mm. No filter was applied for an exposure time of 49 ms. 136 
The images generated were 1944x1413 pixels with a resolution of 17 μm per pixel. Then the data were 137 
collected and Data Viewer as well as CT-An software were used to analyse them. Finally, CTvol 138 
software was applied to generate 3D reconstruction images. 139 
The mechanical properties of the prepared implants were evaluated following a three-point 140 
bending test using a TA-XT2 Texture Analyser (Stable Microsystems, Haslemere, UK). For all 141 
measurements the Texture Analyser was set in compression mode, and a cuboidal probe (9.5 cm in 142 
length) with a sharp end (1.1 mm thick) using a set up previously described by Donnelly et al. [27]. 143 
The probe was moved toward the implant at a speed of 0.5 mm/s. From the peak maximum of the 144 
force-distance curve, the break strength of each implant was calculated. 145 
 146 
2.2.3. Analytical methods 147 
Methylene blue (MB), ibuprofen sodium (IS) and ibuprofen acid (IA) were chosen as model 148 
compounds due to their different solubility’s to assess any effect this may have on the release profiles. 149 
MB was quantified using UV spectroscopy (FLUOstar Omega Microplate Reader, BMG LABTECH, 150 
Ortenberg, Germany) at wavelength of 668 nm. IS and IA were quantified using reverse phase high 151 
performance liquid chromatography (RP-HPLC) (Agilent 1220 series system, Agilent Technologies 152 
UK Ltd, Stockport, UK). The column used to achieve separation was Agilent Eclispe XDB-C18 (5 μm 153 
pore size, 4.6 x 150 mm) column (Agilent Technologies UK Ltd, Stockport, UK). The mobile phase 154 
used was composed of acetonitrile and 0.1% phosphoric acid at a ratio of 70:30, with a flow rate of 155 
1 mL/min, injection volume of 50 μL, and a sample runtime of 5 minutes. UV detection was carried 156 
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out at 220 nm. The mobile phase was degassed by sonication for 30 min prior to use. The column 157 
temperature was regulated to 25 °C. 158 
 159 
2.2.4. In vitro drug release experiments 160 
Implants were loaded with MB, IS or IA and placed in 500 mL of PBS (or PBS with 0.05% sodium 161 
azide for IS and IA release) at 37°C and shaken at 40 rpm. Samples (0.5 mL) of the release medium 162 
were taken at specified time points and replaced with equal volume of PBS [28]. 163 
As well as the agitated vessel in vitro release model, an agarose gel in vitro release model was 164 
also investigated to more closely mimic in vivo conditions [29]. Agarose powder was dissolved in PBS 165 
(for MB release) or PBS containing 0.05% of sodium azide (for IS release) and heated to prepare a 166 
0.6% agarose solution. One third of the required agarose solution was cast into a petri dish (10 cm in 167 
diameter) and the implant (implant design E) was placed in the centre of this and the agarose solution 168 
allowed solidifying. Subsequently, the remaining agarose solution was cast over this initial layer and 169 
allowed to solidify [29]. The petri dishes were then covered with Parafilm M®, to prevent water 170 
evaporation, and placed into an airtight container within a non-agitated incubator at 37°C. 171 
Cylindrical samples (0.5 cm diameter) of agarose were removed at pre-defined time points (Figure 172 
2). Samples were weighed and analysed for their drug content using an appropriate method as 173 
described in section 2.2.3. Due to the symmetry of the agarose gel, it was assumed that the drug 174 
concentration was constant within each zone with the same distance from the implant ‘window’ [29].  175 
 176 
 177 
Figure 2: Schematic illustration of the in vitro experimental setup used to sample drug release into agarose 178 
gel. 179 
 180 
2.3. Data analysis 181 
Release profiles from each of the implants were compared by calculating and comparing the 182 
difference (F1) and similarity (F2) factor. F1 was calculated using Equation (1) that measures the 183 
percentage difference between two curves at each time point and is a measurement of the relative 184 
error between the two curves. Where, n is the number of time points, Rt is the reference dissolution 185 
value at time t, and Tt is the test dissolution value at time t [30,31]. 186 
 187 
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  189 
F2, shown in Equation (2), is a logarithmic transformation of the sum-squared error of differences 190 
between the test and reference products over all time points, n.  191 
 192 
ܨଶ = 50. log{[(1 ݊⁄ ) ∑ (ܴ௧ − ௧ܶ)
௡
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ି଴.ହ. 100}                         (2) 193 
 194 
In order for two dissolution profiles to be considered similar, the F1 value should be lower than 195 
15 (0-15) and F2 value should be more than 50 (50 -100) [30,31]. 196 
Where appropriate all data were expressed as a mean ± standard deviation (SD) and compared 197 
using one-way analysis of variance (ANOVA) with Tukey’s HSD post-hoc. In all cases, P < 0.05 was 198 
the minimum value considered acceptable for rejection of the null hypothesis. 199 
3. Results and discussion 200 
3.1. Implant design and characterisation 201 
A rod shaped implant with a size of 2.5 x 40.0 mm was chosen because this shape and these 202 
dimensions are similar to dimensions that have already been shown to be acceptable in commercially 203 
available products and applicator devices have already been developed for an implant of these 204 
dimensions [32]. Implants were loaded with MB (68.6±5.1 mg), IS (68.1 ±3.0 mg) or IA (72.3 ±3.2 mg). 205 
Images of the produced implants are shown in Figures 3A-H. These images give an appreciation of 206 
the actual geometry of the 3D printed ‘windows’ in comparison to what was designed. Figure 3C and 207 
E show that although the 1.0 x 1.0 mm have been printed the correct size, that they are more circular 208 
in shape than square like the design. This is due to the resolution of FDM printers that is not as high 209 
as the one displayed by other type of 3D printing such as stereolithography [33]. 210 
 211 
Implants A-E loaded with MB, Implants B and E loaded with IS and Implant B loaded with IA 212 
were tested using the agitated vessel release model. Implant E loaded with MB or IS was tested using 213 
the agarose gel release model. IA was not included in the agarose release model because of its poor 214 
solubility and the difficulties this would present to maintain sink conditions. These molecules were 215 
used due to their differing solubility values: MB 40 mg/mL [34]; 100 mg/mL [35]; IA 0.021 mg/mL 216 
[36]. These three molecules cover a wide range of hydrophobicity. Therefore, they are good 217 
candidates to establish how this parameter affects drug release from the 3D printed implantable 218 
devices. The influence of the solubility on the release profiles can be used to anticipate the release 219 
kinetics of other drugs loaded within the implants described here. 220 
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 221 
Figure 3: Images of (A) methylene blue filled implant (Implant B); (B) ibuprofen sodium filled implant 222 
(implant B); (C) Digital microscope image of a section of implant C, (D) A scanning electron microscope 223 
(SEM) image of a section of a 38.0 x 1.0 mm poly(vinyl alcohol) (PVA) membrane, (E) SEM images of a 1.0 224 
x 1.0 mm poly(vinyl alcohol) (PVA) membrane, (F) An image to show the size of the printed implant, (G) 225 
OCT image of a MB filled implant and (H) OCT images of an IS filled implant. Characterisation of implants 226 
through MicroCT analysis. Cross section reconstructions in the y-z plane of the implants containing (I) MB, 227 
and (J) IS. (K) Representative x-y cross section of a 3D printed implant used for quantitative analysis and 228 
dimensional measurements calculated at different locations over the implant 3D volume for the core/ shell 229 
of the samples reported in A) and B) respectively. 230 
The architecture and topology of the 3D printed implants were analysed using a Bruker Skyscan 231 
1172 system μCT (Figures 3I-K). Cross section reconstructions in the y-z plane of an implant 232 
containing I) MB, and J) IS were performed and representative x-y cross section of a 3D printed 233 
implant used for quantitative analysis. These images (Figure 3I and J) give an appreciation of the 234 
drug distribution within the cavity of the implant and shows that the drug distribution is uniform 235 
for both MB and IS. The dimensional measurements calculated at different locations over the implant 236 
3D volume for the core, and shell of the samples are reported in Figure 3K and show that there is no 237 
significant (P>0.05) difference in the size of the drug core for either drug. This indicates that the drugs 238 
were dispersed through the entire implant cavity and that the packing process did not damaged the 239 
implant structure. 240 
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 241 
Figure 4: (A) Implant B (1) OCT images of poly(vinyl alcohol) (PVA) membrane dissolution in implant 242 
B after emersion in PBS; (2) Digital microscope images of poly(vinyl alcohol) (PVA) membrane 243 
dissolution in implant B after emersion in PBS; SEM images of implant B (3) before and (4) after 244 
dissolution. (B) (1) OCT images of poly(vinyl alcohol) (PVA) membrane dissolution in implant E after 245 
emersion in PBS; (2) Digital microscope images of poly(vinyl alcohol) (PVA) membrane dissolution 246 
in implant E after emersion in PBS;  SEM images of implant E (3) before and (4) after dissolution. 247 
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Dissolution of the PVA ‘windows’ in implants B and E were visualised using OCT, digital 248 
microscopy and SEM and are shown in Figures 4A and 4B, respectively. It can be seen that complete 249 
dissolution of the PVA ‘window’ in implant B occurred after 25 min (Figure 4A1). Whereas, complete 250 
dissolution of the PVA ‘window’ in Implant E took 35 min (Figure 4B1). Despite the ‘window’ in 251 
Implant B being significantly larger than the ‘window’ in implant E, it fully dissolved more quickly. 252 
This may be explained by the reduced surface area to volume ratio of the ‘window’ in implant E, 253 
reducing the rate of dissolution for this implant. Goyanes et al. investigated the effect that surface 254 
area to volume ratio had on the dissolution of PVA tablets and reported that a higher surface area to 255 
volume ratio resulted in tablets that dissolved more quickly [37]. It is important to note that the PVA 256 
‘window’ is designed to dissolve quickly to allow drug to diffuse trough the generated ‘window’. 257 
The ‘window’ material can be tailored to achieve a delayed drug release. Additionally, in the last 258 
section of the manuscript an alternative coating approach was described to prepare implants 259 
allowing sustained drug release over months. It is important to note that a commercial quick 260 
dissolving commercial PVA filament was used for this study. PVA is a biocompatible polymer [38] 261 
but commercial filaments can have potential excipients, such as plasticisers, that are not ideal for 262 
medical applications. However, the present work is a proof-of-concept study exploring the influence 263 
of the structure of the implant on the drug release kinetics. Accordingly, a commercial PVA was used 264 
as it was the quickest approach. However, future work will require the use of filaments prepared 265 
using pure biocompatible polymer. This approach opens the possibility of developing implants with 266 
delayed release by printing the implant windows with polymers with slower 267 
dissolution/disintegration kinetics such as cellulose derivatives [39,40]. 268 
 269 
To predict robustness of the designed implants, their break strength and the degree of flexibility 270 
were evaluated. A very rigid implant is likely to break during insertion or in situ; therefore, a degree 271 
of flexibility is required, as well as sufficient strength to withstand insertion and remain mechanically 272 
strong enough for the duration of drug release. If an implant breaks or cracks it is likely to cause an 273 
increase or a burst in the rate of drug release which would, in turn, cause undesirable side-effects in 274 
the patient. The maximum force required breaking the implants and the angle of bending at the break 275 
point was calculated for each implant configuration and shown in Figures 5. 276 
 277 
Figure 5: Force required to break each of the implant designs (n=5, means+SD). 278 
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It can be seen from Figure 5 that there is no significant difference in the break force of implants 279 
B-E (PLA implants). A significantly (p < 0.5) larger force was required to break Implant A (PVA), than 280 
was required for implants B-E. This test was performed to evaluate if changing the design of the 281 
release ‘windows’ from the implant has a direct influence on the mechanical properties of the 282 
resulting material. No directly comparable mechanical tests to those performed in this study have 283 
been performed on commercially available implantable drug delivery devices. However, mechanical 284 
testing of medical devices has been extensively reported. The results obtained here can be compared 285 
with the results reported by Horal et al. for 3D printed PLA screws for orthopaedic applications [41]. 286 
In this case, PLA screws were manufactured and a three-point bending test was performed. The 287 
dimensions of these implants were similar to the ones described here (1-2 mm) and the forces applied 288 
during the bending tests were lower than the ones reported here (ranging between 0.5 and 10N). 289 
These screws where designed for bone healing applications. Higher forces will be applied to bone 290 
screws than to implants designed to be implanted in soft tissue. Therefore, the implants presented 291 
here showed fracture forces higher than the forces that will be expected for soft tissue implants. As 292 
PLA has a long degradation time, up to 2 years [42], degradation of the implant structure would not 293 
be expected to have an effect on the mechanical properties during drug release or an effect on the 294 
release rate itself. 295 
 296 
3.3. In vitro drug release 297 
MB has some inherent antibacterial activity, therefore, bacterial growth in the release media was 298 
not anticipated to be an issue for these implants [43]. However, SA was added to IS and IA release 299 
media to prevent microbial growth [23,44,45] over the course of the release experiment. The release 300 
profiles of MB from each of the five implant designs are shown in Figure 6. Implants made entirely 301 
from PVA (implant A) had the most rapid drug release, with 100% of drug releasing within 24 hours. 302 
As expected, implants B and C showed significantly extended release profiles in comparison with 303 
implant A, with release time being extended to over six days. Although, implant B and C took the 304 
same time to reach 100% release, Implant C showed a more sustained release profile, which showed 305 
less variation. Implants D and E showed an extended release profile in comparison to the other 306 
implants and shows that reducing the size and number of ‘windows’ effectively prolongs release 307 
from this type of implant. The release profiles of MB from each of the PVA ‘window’ implants were 308 
compared using similarity and difference factor (F1/F2) and the results are shown in Table 1. Implant 309 
A had a significantly different release profile to implants B and C as the F1 values are higher than 15 310 
and the F2 values are lower than 50. Implants B and C, and implants D and E also showed significantly 311 
different release profiles to each other. These results indicate that implant design has potential to 312 
modify the release profile of a loaded molecule by simply changing the design of the implant. 313 
Interestingly, implants with 1.0 x1.0 mm ‘windows’ were capable of providing drug release over 25 314 
days. A sustained release profile like this can be useful for local antimicrobial therapy or for pain 315 
management after surgery [46,47]. In these cases, a prolonged release over a period of a few weeks 316 
can be extremely beneficial to prevent infections or for pain management. However, for prolonged 317 
applications alternative approaches need to be evaluated. For this purpose, coated implants were 318 
evaluated. This approach will be described in section 3.5 of the present manuscript. 319 
 320 
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 321 
Figure 6: Release of methylene blue (MB) from (A) implant A-C; (B) implant D and E (n=3, means ± 322 
SD) and (C) Correlation between MB release rate and ‘window’ area for the implants. 323 
Table 1: Difference (F1) and similarity (F2) factor of each release profile for methylene blue (MB) 324 
release from poly(lactic acid) (PLA) implant with poly(vinyl alcohol) (PVA) ‘window’ designs. 325 
Curve 1 Curve 2 F1 F2 
Implant A Implant B 60.06 33.00 
Implant A Implant C 73.89 13.58 
Implant B Implant C 28.93 32.12 
Implant D Implant E 19.61 34.75 
 326 
The effect of drug properties on release from the designed implants was investigated by 327 
comparing the release profiles of MB (solubility – 40 mg/mL [34]), with IS (solubility –100 mg/mL 328 
[35]) and IA (solubility – 0.021 mg/mL [36]). The release profiles of IS from implant B and E are shown 329 
in Figure 7A. The release rate of IS from implant B was significantly increased in comparison to MB 330 
from the same implant. Complete IS release was achieved after just 80 minutes, whereas, 100% MB 331 
release took seven days. A similar increase in release rate is seen for implant E, with 100% IS release 332 
achieved after six days and MB release after 25 days. These results show that obviously the implant 333 
design is not the only factor that contributes to change the release profile. The physicochemical 334 
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properties of the drug loaded are important too. All in vitro releases were carried out under sink 335 
conditions; therefore, it is dissolution rate of each of the drugs rather than solubility that is having an 336 
impact on drug release from the implant. Accordingly, changing the nature of the loaded molecule 337 
or by including a formulation with a slower dissolution rate will provide an extra degree of control 338 
over the release profile.  339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
Figure 7: Release of (A) ibuprofen sodium (IS) from Implant B; (B) IS Implant E and (C) Release of 347 
ibuprofen acid (IA) from implant B (n=3, means ± SD). 348 
IA release from implant B is shown in Figure 7C. The release of this compound is significantly 349 
extended in comparison with MB and IS release from the same implant design, with release taking 350 
ten days in comparison to six days and 80 minutes for MB and IS, respectively. As mentioned 351 
previously, the release rate of this drug is slower due to its slower dissolution kinetics confirming 352 
that the nature of the drug loaded need to be carefully considered for each application type.  353 
Figure 8 shows the release profiles of MB and IS from implant E into an agarose gel release 354 
model. Release is expected to be slower in the agarose gel when compared to the agitated vessel 355 
release model. Within the agitated vessel model, convection rapidly homogenises the drug within 356 
the release media, thus, maintaining the drug concentration gradient at the interface of the implant 357 
with the release media. However, living tissues exhibit different conditions than those applied in the 358 
in vitro – agitated vessel method. The extracellular matrix that these formulations are likely to be in 359 
contact with after implantation behave more like a gel than bulk fluid [48]. Despite existence of a 360 
large number of biorelevant media for simulating physiological fluids, there is still not an accepted 361 
standard for simulation of sub-cutaneous environment [48]. Agarose gels form a 3D structure linked 362 
by hydrogen bonds with pore sizes similar to those encountered in physiological tissue and have 363 
been suggested as a more realistic in vitro release model than bulk fluid [29,49]. Moreover, multiple 364 
research works have reported the suitability of agarose hydrogel as a good release medium 365 
simulating soft tissues [50–53]. 366 
 Both drugs demonstrated progressive drug release over a prolonged period. Figures 8A-B show 367 
the release obtained for MB loaded implants. These results showed that the closest region (1.5 cm) to 368 
the implant reached a plateau in MB levels after 7 days. However, in further regions the MB 369 
concentration increased over time up to 40 days for the further regions (4.5 cm). This shows that MB 370 
was continuously delivered over 40 days. This MB concentration increase is not due only to MB 371 
diffusion through the agarose gel as the concentration always increased. This suggests that there was 372 
a constant MB release that took place over time. After 40 days no significant differences were found 373 
in the release obtained at different distances from the implant (P>0.05). This indicated that MB 374 
concentration all over the agarose gel was equivalent and that there was no concentration gradient 375 
that will drive more release. Similar behaviour was observed for IS (Figure 8C-D) over a period of 21 376 
(A) (B) (C) 
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days. These results confirm that the testing conditions had a substantial influence on the release 377 
results. Moreover, this set of results suggest that the selected implants can be used to provide drug 378 
release over periods of several weeks. Similarly, Hoang et al. investigated releases of ciprofloxacin 379 
hydrochloride and vancomycin hydrochloride from bone implants over 48 and 96 hours, respectively 380 
and showed that release into an agarose model was extended when compared to release of the same 381 
drugs from the same implants into an agitated vial [29]. 382 
 383 
 Figure 8: (A and B) MB and (C and D) IS releases from (A) implant E into Agarose gel. (n=3, means 384 
± SD) 385 
The releases achieved in this work range from just 80 minutes to over 25 days in an agitated 386 
vessel and over 40 days in an agarose gel model and show promise as drug delivery systems 387 
prolonged drug delivery. The use of local anaesthetics (commonly, bupivacaine, lidocaine and 388 
procaine) to treat localised pain has many advantages when compared with the systemic 389 
administration of opioids [14]. Work has been carried out to optimise the drug delivery of these 390 
agents to achieve localised delivery and limit peripheral side effects. An implantable device that 391 
could locally deliver anaesthetic over days or weeks could be of benefit for delivery of these drugs. 392 
Currently, the majority of chemotherapeutic agents are delivery systemically. This allows the drug 393 
to distribute throughout the entire body, including to healthy tissues, causing adverse side 394 
effects [54]. Polymeric devices aiming to locally deliver cancer drugs have been investigated and aim 395 
to improve the delivery of these drugs by providing localised sustained delivery and, therefore, 396 
reduce the effect on healthy tissue. Salmoria et al. investigated the use of polymeric implant to locally 397 
deliver fluorouracil and showed a desirable release rate over 45 days [54]. Localised delivery of 398 
antibiotics may offer advantages over conventional oral delivery for localised conditions. Gimeno et 399 
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al. showed promising delivery of antibiotics which could be tailored by changing the implant design, 400 
from rapid drug release within 20 hours to longer release times around 200 hours for the potential 401 
prevention of orthopaedic-implant associated infections [15]. These examples highlight instances 402 
where the implants developed in this work could be used. 403 
3.4. In Vitro drug release from coated implants 404 
The results described in previous sections show that these implants can be used for sustained 405 
drug delivery over periods of several weeks. The treatment of some medical conditions, especially 406 
chronic conditions, can be improved significantly with drug delivery devices capable of providing 407 
drug release over prolonged periods of time. These periods of time range from months up to years 408 
for potent compounds such as hormones. Examples of this will be the treatment of chronic conditions 409 
or even pre-exposure prophylaxis of human immunodeficiency disease (HIV).  410 
A good alternative to obtain implants with prolonged drug release profiles is to coat them with 411 
a membrane capable of sustaining drug release [55]. Accordingly, a simple dip coating procedure can 412 
be used to prepare implants with prolonged drug release profiles. Accordingly, a thin film covers the 413 
surface of the implant acting as a rate controlling membrane [9]. Figure 9 shows the release profile of 414 
MB from implants (Implant B) coated with a PCL-based formulation. It can be seen that the PCL rate 415 
controlling membrane is capable of providing sustained drug releases over periods of 300 days. 416 
Interestingly, non-coated equivalent implants showed MB release profiles extended over only 4 days 417 
(Figure 6). These results suggest that PCL coating could be an ideal approach for applications that 418 
require drug release over longer periods of time. PCL has been described previously as a good 419 
candidate to prepare rate controlling membranes for drug delivery applications [9]. PEG membranes 420 
have been used before to release tenofovir alafenamide for HIV pre-exposure prophylaxis [56]. These 421 
systems achieved prolonged releases between 100 and 200 days. Considering that tenofovir 422 
alafenamide shows a lower water solubility than MB, the system described has great potential for 423 
sustaining the release of hydrophilic molecules as MB showed up to 300 days of release. 424 
 425 
 426 
 427 
 428 
 429 
 430 
 431 
 432 
 433 
 434 
 435 
Figure 9: Release profile of methylene blue from implant B with a PCL formulation coating (n=3, 436 
means ± SD). 437 
4. Conclusions 438 
In this work, hollow 3D printed implants with similar dimensions to those already available in 439 
the market, were successfully produced. The flexibility of this manufacturing technique allowed five 440 
different implant designs to be easily designed and produced. This technique has the potential to 441 
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allow personalisation of implantable drug delivery devices for individual patients and conditions. 442 
μCT confirmed consistent drug distribution within the implant and confirms the implants suitability 443 
for a range of drug compounds. The mechanical properties of the designed implants were superior 444 
to other drug delivery systems. This work has shown that the release rate from these implants can be 445 
modified by changing the implant design, but is also dependent on the properties of the compound 446 
contained within the implant. Finally, implant coating can provide an added degree of control over 447 
the release, with PCL-based coating shown potential to extend expressively the release profile. 448 
The results described in the present work demonstrate how 3D printing is a promising 449 
technology for drug eluting implant manufacture. Considering the simplicity of the technology 450 
described here, it can be easily transferred to a clinical setup, where implants could be designed on 451 
demand to fulfil patient’s needs after surgery. These implants may be suited for delivery of drugs for 452 
localised treatment. For example, chemotherapy agents, antibiotics or localised anaesthetics. 453 
Alternatively, they could be tailored by coating them for prolonged drug delivery for the treatment 454 
of chronic conditions. This can be done due to the versatility of 3D printing technology. 455 
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